Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The oral use of the drug Piavit (derived from freeze-dried medicinal leeches) in 50 patients with coronary heart disease for 7 days in a daily dose of 600 mg (20 patients) and 1200 mg (30 patients) caused a moderate dose-independent increase in enzymatic, fibrinolysis, non-enzymatic fibrinolysis and antithrombin III activity. In half the patients who had low fibrinolytic levels, the agent stimulated mainly the release of plasminogen activator on administration days of 2 and 7. In other 15 patients the activity of plasminogen activator remained unchanged, but non-enzymatic fibrinolysis enhanced. Piavit prolonged the hypocoagulative effect of heparin and aspirin in the group of patients pretreated with these drugs. There were no clinical manifestations of the disease during 7 days.
 ...
PMID:[The effect of piyavit on hemostatic processes and fibrinolysis in patients with ischemic heart disease]. 766 90

Thrombin inhibitors from bloodsucking leeches and insects that block conversion of fibrinogen to fibrin are considered. Regulatory mechanisms influencing the fibrinogen-fibrin system in leeches include fibrinogen degradation, inhibition of factor XIIIa, and lysis of fibrin clots. The review also summarizes recent data on plasminogen activator from the vampire bat Desmodus rotundus and a role of fibrin as its cofactor.
 ...
PMID:Fibrinogen-fibrin system regulators from bloodsuckers. 1184 48

Nature has provided a vast array of bioactive compounds that have been exploited for either diagnostic or therapeutic use. The field of thrombosis and haemostasis in particular has enjoyed much benefit from compounds derived from nature, notably from snakes and blood-feeding animals. Indeed, the likelihood that blood-feeding animals would harbour reagents with relevant pharmacology and with potential pharmaceutical benefit in haemostasis was not too far-fetched. Blood-feeding animals including leeches and ticks have evolved a means to keep blood from clotting or to at least maintain the liquid state, and some of these have been the subject of clinical development. A more recent example of this has been the saliva of the common vampire bat Desmodus rotundus, which has proven to harbour a veritable treasure trove of novel regulatory molecules. Among the bioactive compounds present is a fibrinolytic compound that was shown over 40 years ago to be a potent plasminogen activator. Studies of this vampire bat-derived plasminogen activator, more recently referred to as desmoteplase, revealed that this protease shared a number of structural and functional similarities to the human fibrinolytic protease, tissue-type plasminogen activator (t-PA) yet harboured critically important differences that have rendered this molecule attractive for clinical development for patients with ischaemic stroke.
 ...
PMID:Desmoteplase: discovery, insights and opportunities for ischaemic stroke. 2162 37